Multivariate analysis of factors associated with PFS in all patients with POAML and and Ann Arbor stage I disease
| Factor . | Coefficient . | z score . | PFS (P value) . |
|---|---|---|---|
| Patients with POAML | |||
| Age (>60 y vs ≤60 y) | 0.862 | 2.44 | .015 |
| Eye involvement (bilateral vs unilateral) | 0.108 | 0.22 | NS |
| RT dose (≥30.6 Gy vs <30.6 Gy) | −1.484 | −4.18 | .00003 |
| Stage (I vs II to IV) | 1.05 | 1.60 | NS |
| Patients with Ann Arbor stage I | |||
| Age (>60 y vs ≤60 y) | 1.15 | 3.02 | .0025 |
| Eye involvement (unilateral vs bilateral) | −0.26 | −0.50 | NS |
| RT dose (≥30.6 Gy vs <30.6 Gy) | −1.74 | −4.59 | .000004 |
| Factor . | Coefficient . | z score . | PFS (P value) . |
|---|---|---|---|
| Patients with POAML | |||
| Age (>60 y vs ≤60 y) | 0.862 | 2.44 | .015 |
| Eye involvement (bilateral vs unilateral) | 0.108 | 0.22 | NS |
| RT dose (≥30.6 Gy vs <30.6 Gy) | −1.484 | −4.18 | .00003 |
| Stage (I vs II to IV) | 1.05 | 1.60 | NS |
| Patients with Ann Arbor stage I | |||
| Age (>60 y vs ≤60 y) | 1.15 | 3.02 | .0025 |
| Eye involvement (unilateral vs bilateral) | −0.26 | −0.50 | NS |
| RT dose (≥30.6 Gy vs <30.6 Gy) | −1.74 | −4.59 | .000004 |
NS, not significant.